NIH

Growth was driven by demand in its life science segment, particularly for COVID-19-related products, while the diagnostics segment saw uneven improvement.

The bill, which Congress overwhelmingly approved last week, also includes additional funding for the US Centers for Disease Control and Prevention.

The bill, which was overwhelming passed by both the Senate and the House, would boost the National Institutes of Health's budget by $1.25 billion.

The agency also helped fund the development of the Revogene SARS-CoV-2 assay, which detects RNA targets directly from viral transport media without pre-dilution.

The company said it will use the funding to integrate Oxford Nanopore Technologies' ultra-long read genomic sequencing into its service.

Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago, and well above analysts' consensus estimate of $32.5 million.

The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.